Neurological Diseases
15
1
1
9
Key Insights
Highlights
Success Rate
90% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
6.7%
1 terminated out of 15 trials
90.0%
+3.4% vs benchmark
7%
1 trials in Phase 3/4
0%
0 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 9 completed trials
Clinical Trials (15)
Autoimmune Neurological Diseases and Those Secondary to Immunotherapy: Study of Immunological Mechanisms and Research Into Targets of Immune Attack
Rapid Declarative Neocortical Declarative Learning in Aging and Memory Diseases (ANéRAVIMM)
In Vivo and ex Vivo Validation of MR Tractography of Brain White Matter Tracts - FIBRATLAS II-III
Allogeneic Cord Blood for Neurological Diseases in Adults
Impact of Home-Based Rehabilitation on Motor Function and Mood in Individuals With Disabilities
Rehabilitation With Biofeedback in Neurology
Telepalliation - Digital Platform for Patients in Palliation and Their Relatives
Adjustment Exploratory Protocols and Functional Evaluation of New Non Invasive Devices in Patient Volunteers
Establishment of Clinical Basis for Hematopoietic Growth Factors Therapy in Brain Injury
Prognosis in Neurological Intensive Care Unit Patients (proNICU Cohort)
Evaluating the Impact That Personnel Traffic Through the Operating Room Has on Surgical Site Infections
Progressive Resistance Strength Training (PRT) in Hospitalised Elderly Patients
Finding Genes With NGS Techniques in Whom Mutations Cause Neurological Diseases
Nutritional and Metabolic Evaluation of a Tube Feeding Immune Enhancing Diet in ICU Patients
In Vitro NMR Spectroscopy in Neurological Diseases